

Basic information	
<b>2023/2771(DEA)</b> DEA - Delegated acts procedure	Procedure completed - delegated act enters into force
Adjustment to the inflation rate of the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use  Supplementing <a href="#">2013/0222(COD)</a>	
<b>Subject</b>  4.20.04 Pharmaceutical products and industry 8.40.08 Agencies and bodies of the EU	

Key players			
European Parliament	Committee responsible	Rapporteur	Appointed
	<div>ENVI</div> Environment, Public Health and Food Safety		

Key events			
Date	Event	Reference	Summary
29/06/2023	Non-legislative basic document published	<a href="#">C(2023)04261</a>	
29/06/2023	Initial period for examining delegated act 2 month(s)		
12/07/2023	Committee referral announced in Parliament		
06/09/2023	Delegated act not objected by Parliament		

Technical information	
Procedure reference	2023/2771(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
Amendments and repeals	Supplementing <a href="#">2013/0222(COD)</a>
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	ENVI/9/12404

Documentation gateway			
European Commission			
Document type	Reference	Date	Summary

Non-legislative basic document	C(2023)04261	29/06/2023	

## Meetings with interest representatives published in line with the Rules of Procedure

### Other Members

Transparency		
Name	Date	Interest representatives
FITZGERALD Frances	22/06/2023	Roche Products Ireland
FITZGERALD Frances	03/05/2023	Baxter Healthcare SA